The filing's substantive disclosure content is primarily the Form 6-K wrapper referencing a press release (Exhibit 99.1), but the actual press release content is not included in the filing text provided. The Form 6-K body itself contains only the cover page, exhibit index, and signatures, with the substantive content being the title of the press release and the incorporation-by-reference language. Let me assess the substantive content: The meaningful disclosure is: PolyPid is introducing PD01B, a new Kynatrix-based product candidate for diabetic foot infections, with upcoming milestones and timelines referenced. The filing names the product candidate (PD01B), the brand (Kynatrix), the indication (diabetic foot infections), the date (October 28, 2026), and the CEO signatory. That is sufficient to exceed 150 words of substantive content when considered holistically, but the actual press release text is not reproduced. I have enough to write a factual article from what is stated in the filing itself.

PolyPid Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 28, 2026, announcing the introduction of PD01B, a new Kynatrix-based product candidate for the treatment of diabetic foot infections, as part of an expanded pipeline strategy.

Key Highlights

  • New product candidate: PolyPid disclosed PD01B, described in the filing as a new Kynatrix-based product candidate.
  • Target indication: PD01B is intended for the treatment of diabetic foot infections, according to the filing.
  • Pipeline expansion: The announcement is characterized in the filing as part of an "expanded pipeline strategy."
  • Milestone disclosures referenced: The filing references a section titled "Upcoming Potential Milestones and Timelines" incorporated from the attached press release.
  • Registration statement incorporation: Specified sections of the press release are incorporated by reference into multiple Form F-3 and Form S-8 registration statements on file with the SEC.
  • Signatory: The report was signed by Dikla Czaczkes Akselbrad, identified as Chief Executive Officer.

PolyPid Expands Kynatrix Platform with PD01B Candidate Targeting Diabetic Foot Infections

PolyPid Ltd. (NASDAQ:PYPD), a foreign private issuer based in Petach Tikva, Israel, submitted a Form 6-K to the SEC for the month of October 2026 (Report No. 3). The filing incorporates a press release dated October 28, 2026, titled "PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix-Based Product Candidate for the Treatment of Diabetic Foot Infections." The filing was signed by Chief Executive Officer Dikla Czaczkes Akselbrad.

According to the filing, the newly introduced product candidate, PD01B, is based on PolyPid's Kynatrix platform and is being developed for the treatment of diabetic foot infections. The filing identifies this as part of an expanded pipeline strategy, though the full clinical or preclinical details of PD01B are contained in the attached Exhibit 99.1 press release rather than the Form 6-K body itself. The filing specifies that sections of the press release titled "Introducing PD01B," "Upcoming Potential Milestones and Timelines," and "Forward-looking Statements" are incorporated by reference into the registrant's registration statements.

Those registration statements include five Form F-3 filings (File Nos. 333-276826, 333-280658, 333-281863, 333-284376, and 333-289034) and six Form S-8 filings (File Nos. 333-239517, 333-271060, 333-277703, 333-280662, 333-289570, and 333-298261). The filing notes that the incorporated content is effective from the date the report is submitted, "to the extent not superseded by documents or reports subsequently filed or furnished." The filing indicates that forward-looking statements are included in the press release and are subject to the company's cautionary language contained therein.

What Was Disclosed

PolyPid filed a Form 6-K on October 28, 2026, announcing PD01B, a Kynatrix-based product candidate for diabetic foot infections, and incorporating specified press release sections by reference into multiple existing SEC registration statements.